MiguelAngelMaterinMD

Ocular Oncology

Physician

Dr. Materin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Miguel Materin is an ophthalmologist in Durham, NC and is affiliated with Duke University Hospital.

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

PubMed

Yttrium-90 (Y) brachytherapy for squamous carcinoma: Treatment of the conjunctiva, cornea, and sclera.
Arpita Maniar, Junzo Chino, Sheridan Meltsner, Paul T Finger, Miguel A Materin
American Journal of Ophthalmology Case Reports. 2024-12-01
2 citations
15-Gene Expression Profile andas Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1).
J William Harbour, Zelia M Correa, Amy C Schefler, Prithvi Mruthyunjaya, Miguel A Materin
Journal of Clinical Oncology. 2024-10-01
Melanocytic Nevus of the Superior Conjunctival Fornix: A Case Report.
Modupe O Adetunji, Thomas J Cummings, Miguel A Materin, Arpita S Maniar
Case Reports in Ophthalmology. 2024-03-18

Metastatic Uveal Melanoma: New Drugs in Pipeline, but Prognoses Remain GrimDecember 14th, 2021
Practice Patterns for the Treatment of Uveal Melanoma with Iodine-125 Plaque Brachytherapy: Ocular Oncology Study Consortium Report 5May 1st, 2020